What's Happening?
The Jackson Laboratory, in collaboration with the Broad Institute and other partners, has been awarded a contract of up to $34.5 million by the Advanced Research Projects Agency for Health (ARPA-H). This funding is part of the THRIVE initiative, aimed
at developing a gene editing platform for pediatric epilepsies and rare central nervous system (CNS) diseases. The project, known as the Pediatric Epilepsies & Rare CNS (PERC) Gene Editing Platform, focuses on advancing precision genetic medicines for severe childhood neurologic diseases such as alternating hemiplegia of childhood (AHC) and Dravet syndrome. The initiative seeks to create a scalable, systematic approach to genetic medicine, moving beyond the traditional drug development model that is often unsuitable for rare diseases.
Why It's Important?
This initiative is significant as it addresses the urgent need for effective treatments for rare pediatric CNS diseases, which often result in severe neurological impairment and high mortality rates in children. By developing a scalable gene editing platform, the project aims to streamline the process of creating precision genetic medicines, potentially transforming the treatment landscape for rare diseases. This could lead to faster, more efficient development of therapies, benefiting patients who currently have limited or no treatment options. The collaboration also highlights a broader federal effort to enhance U.S. leadership in clinical research and accelerate the development of life-saving treatments.
What's Next?
The project will initially focus on advancing gene-editing approaches for AHC and Dravet syndrome, with plans to generate the necessary evidence for first-in-human studies. The long-term goal is to build a reproducible platform that can be adapted to other rare neurogenetic diseases. The collaboration involves multiple institutions, including Boston Children's Hospital and the RARE Hope Foundation, combining expertise in gene-editing innovation, preclinical translation, and clinical development. This effort is part of a larger federal push to modernize clinical research and improve trial efficiency, potentially setting a precedent for future initiatives in rare disease treatment.
